Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional ...
Research and Development (R&D) Expenses: R&D expense was $32.7 million for the first quarter of 2026, as compared to $19.6 ...
Blavity on MSN
Kehlani on navigating life with bipolar disorder and BPD
In the world of contemporary R&B, Kehlani has long been celebrated for a radical brand of transparency that mirrors the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results